Obesity increases the risk of endometrial cancer, with higher Body Mass Index (BMI) leading to a significant increase in both cancer risk and recurrence. Because of the excellent cancer-specific outcomes and preponderance of obesity-related complications, women with endometrial cancer are more likely to die of cardiovascular disease and other obesity-related illnesses than endometrial cancer itself. This makes an endometrial cancer diagnosis a critical moment to emphasizes the importance of actively managing the underlying issue of obesity in the endometrial cancer survivorship period. Bariatric surgery has shown long-term benefits, including weight loss and reduction of obesity-related comorbidities, and has been linked to a decrease in endometrial cancer incidence. However, bariatric surgery has limitations, such as irreversibility and potential complications. Recent interest in less invasive methods, like bariatric endoscopy, shows promising results in achieving weight loss and improving metabolic profiles. Endoscopic procedures, such as Endomina Endoscopic suture gastroplasty (E-ESG), have shown effectiveness in weight loss and could offer a safer, more accessible alternative to surgery, in particular if associated to a lifestyle modifications program. Efficacy and safety of Bariatric endoscopy has been stressed within the recently published "Guideline of the Italian Society of Surgery of Obesity and Metabolic Diseases on Bariatric Endoscopy in the treatment of obesity and associated complications" that suggest the use of bariatric endoscopy in patients with class I obesity and in patients with class II obesity regardless of the presence of comorbidities, for the treatment of obesity. This study aims to assess the feasibility and safety of the E-ESG procedure in treating obesity in women after curative treatment for endometrial cancer.
Obesity increases the risk of endometrial cancer, with higher BMI leading to a significant increase in both cancer risk and recurrence. Because of the excellent cancer-specific outcomes and preponderance of obesity-related complications, women with endometrial cancer are more likely to die of cardiovascular disease and other obesity-related illnesses than endometrial cancer itself. This makes an endometrial cancer diagnosis a critical moment to emphasizes the importance of actively managing the underlying issue of obesity in the endometrial cancer survivorship period. Bariatric surgery has shown long-term benefits, including weight loss and reduction of obesity-related comorbidities, and has been linked to a decrease in endometrial cancer incidence. However, bariatric surgery has limitations, such as irreversibility and potential complications. Recent interest in less invasive methods, like bariatric endoscopy, shows promising results in achieving weight loss and improving metabolic profiles. Endoscopic procedures, such as Endomina Endoscopic suture gastroplasty (E-ESG), have shown effectiveness in weight loss and could offer a safer, more accessible alternative to surgery, in particular if associated to a lifestyle modifications program. Efficacy and safety of Bariatric endoscopy has been stressed within the recently published "Guideline of the Italian Society of Surgery of Obesity and Metabolic Diseases on Bariatric Endoscopy in the treatment of obesity and associated complications" that suggest the use of bariatric endoscopy in patients with class I obesity and in patients with class II obesity regardless of the presence of comorbidities, for the treatment of obesity. This study aims to assess the feasibility and safety of the E-ESG procedure in treating obesity in women after curative treatment for endometrial cancer.
Study Type
OBSERVATIONAL
Enrollment
74
Centro di Riferimento Oncologico (CRO) - IRCCS Aviano
Aviano, Pordenone, Italy
RECRUITINGFondazione Policlinico Universitario Campus Bio-Medico
Roma, Roma, Italy
NOT_YET_RECRUITINGEvaluation of the feasibility of E-ESG procedure in obese patients with endometrial cancer.
Absolute and relative frequency of patients with technical success of E-ESG procedure, reported with relative 95% Confidence Interval
Time frame: up to 4 years
Evaluation of patients who refused E-ESG procedure
Evaluation of the number and percentage of women with endometrial cancer and obese who refused E-ESG procedure
Time frame: up to 4 years
Evaluation of patients who refused E-ESG procedure
Description with absolute and relative frequencies of baseline characteristics of women with endometrial cancer and obese who refused E-ESG procedure
Time frame: up to 4 years
Evaluation of E-ESG safety in obese endometrial cancer patients.
Absolute and relative frequencies of adverse events
Time frame: up to 4 years
To evaluate efficacy of E-ESG effects on obesity-associated comorbidities.
Evaluation of % Excess weight loss (EWL) with the formula (Weight loss)/ (Excess weight at T0) x 100 and %TBWL(total body weight loss) with the formula (weight loss) / (weight at T0) x 100 in enrolled patients at 1 year
Time frame: up to 4 years
Evaluation of percentage of patients that reach a mean excess weight loss (EWL) of more than 25% and total body weight loss (TBWL) of more than 5% maintained at 1 year (52 weeks) in E-ESG and lifestyle modifications group
Absolute and relative frequencies of patients that reach a mean excess weight loss (EWL) of more than 25% and a total body weight loss (TBWL) of more than 5% maintained at 1 year (52 weeks)
Time frame: up to 4 years
To evaluate the change of metabolic serum biomarkers in E-ESG patients
Mean or median difference between baseline values of metabolic serum biomarkers and 52 weeks (T1), and 156 weeks (T2)
Time frame: up to 4 years
To evaluate the change of gut microbiota
Microbial levels will be described as mean or median, reporting differences in levels ad different time points
Time frame: up to 4 years
To evaluate Overall Survival in E-ESG
Overall survival will be defined as time between E-ESG and death from any cause or end of follow up, whichever cames first. Data will be described as median survival and interquartile range (IQR) calculated with Kaplan-Meyer method
Time frame: up to 4 years
To evaluate Disease Free Survival n E-ESG
Overall survival will be defined as time between E-ESG and disease progression or death from any cause or end of follow up, whichever cames first. Data will be described as median survival and interquartile range (IQR) calculated with Kaplan-Meyer method
Time frame: up to 4 years
To evaluate Recurrence rate in E-ESG
Disease recurrence rate at the end of follow up will be reported as absolute and relative frequency
Time frame: up to 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.